SK Biopharmaceuticals said on March 28 it is speeding up the development of a sleep disorder treatment with plans to file an application with the US Food and Drug Administration this year, reports The Investor.

In 2011, the company signed a deal with Jazz Pharmaceutical to grant it an exclusive worldwide license to develop and commercialize SKL-No5 with a therapeutic focus on treating sleep disorders.